Top

Breast Cancer Research and Treatment

Published in:

Open Access 01-01-2019 | Clinical trial

High patient satisfaction with a simplified BRCA1/2 testing procedure: long-term results of a prospective study

Authors: Martin P. Nilsson, Erik D. Nilsson, Åke Borg, Yvonne Brandberg, Barbro Silfverberg, Niklas Loman

Published in: Breast Cancer Research and Treatment | Issue 2/2019

Abstract

Purpose

In the BRCAsearch study, unselected breast cancer patients were prospectively offered germline BRCA1/2 mutation testing through a simplified testing procedure. The purpose of the present study was to evaluate satisfaction with the BRCAsearch testing procedure and, furthermore, to report on uptake rates of prophylactic surgeries among mutation carriers.

Methods

Pre-test information was provided by a standardized invitation letter instead of in-person genetic counseling. The patients were offered contact with a genetic counselor for telephone genetic counseling if they felt a need for that. Mutation carriers were telephoned and given a time for a face-to-face post-test genetic counseling appointment. Non-carriers were informed about the test result through a letter. One year after the test results were delivered, a study-specific questionnaire was mailed to the study participants who had consented to testing. The response rate was 83.1% (448 of 539).

Results

A great majority (96.0%) of the responders were content with the method used for providing information within the study, and 98.7% were content with having pursued genetic testing. 11.1% answered that they would have liked to receive more oral information. In an adjusted logistic regression model, patients with somatic comorbidity (OR 2.56; P = 0.02) and patients born outside of Sweden (OR 3.54; P = 0.01) were more likely, and patients with occupations requiring at least 3 years of university or college education (OR 0.37; P = 0.06) were less likely to wanting to receive more oral information. All 11 mutation carriers attended post-test genetic counseling. At a median follow-up of 2 years, the uptake of prophylactic salpingo-oophorectomy was 100%, and the uptake of prophylactic mastectomy was 55%.

Conclusions

Satisfaction with a simplified BRCA1/2 testing procedure was very high. Written pre-test information has now replaced in-person pre-test counseling for breast cancer patients in our health care region.

Available only for authorised users

Hoberg-Vetti H, Bjorvatn C, Fiane BE, Aas T, Woie K, Espelid H, Rusken T, Eikesdal HP, Listol W, Haavind MT, Knappskog PM, Haukanes BI, Steen VM, Hoogerbrugge N (2016) BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study. Eur J Hum Genet 24(6):881–888. https://doi.org/10.1038/ejhg.2015.196 CrossRefPubMed

Kinney AY, Steffen LE, Brumbach BH, Kohlmann W, Du R, Lee JH, Gammon A, Butler K, Buys SS, Stroup AM, Campo RA, Flores KG, Mandelblatt JS, Schwartz MD (2016) Randomized noninferiority trial of telephone delivery of BRCA1/2 genetic counseling compared with in-person counseling: 1-year follow-up. J Clin Oncol 34(24):2914–2924. https://doi.org/10.1200/jco.2015.65.9557 CrossRefPubMedPubMedCentral

Metcalfe KA, Poll A, Royer R, Llacuachaqui M, Tulman A, Sun P, Narod SA (2010) Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol 28(3):387–391. https://doi.org/10.1200/jco.2009.25.0712 CrossRefPubMed

Schwartz MD, Valdimarsdottir HB, Peshkin BN, Mandelblatt J, Nusbaum R, Huang AT, Chang Y, Graves K, Isaacs C, Wood M, McKinnon W, Garber J, McCormick S, Kinney AY, Luta G, Kelleher S, Leventhal KG, Vegella P, Tong A, King L (2014) Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer. J Clin Oncol 32(7):618–626. https://doi.org/10.1200/jco.2013.51.3226 CrossRefPubMedPubMedCentral

Sie AS, van Zelst-Stams WA, Spruijt L, Mensenkamp AR, Ligtenberg MJ, Brunner HG, Prins JB, Hoogerbrugge N (2014) More breast cancer patients prefer BRCA-mutation testing without prior face-to-face genetic counseling. Fam Cancer 13(2):143–151. https://doi.org/10.1007/s10689-013-9686-z CrossRefPubMed

Nilsson MP, Torngren T, Henriksson K, Kristoffersson U, Kvist A, Silfverberg B, Borg A, Loman N (2018) BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer. Breast Cancer Res Treat 168(1):117–126. https://doi.org/10.1007/s10549-017-4584-y CrossRefPubMed

Metcalfe KA, Poll A, Llacuachaqui M, Nanda S, Tulman A, Mian N, Sun P, Narod SA (2010) Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2. Clin Genet 78(5):411–417. https://doi.org/10.1111/j.1399-0004.2010.01499.x CrossRefPubMed

Peshkin BN, Kelly S, Nusbaum RH, Similuk M, DeMarco TA, Hooker GW, Valdimarsdottir HB, Forman AD, Joines JR, Davis C, McCormick SR, McKinnon W, Graves KD, Isaacs C, Garber J, Wood M, Jandorf L, Schwartz MD (2016) Patient perceptions of telephone vs. in-person BRCA1/BRCA2 genetic counseling. J Genet couns 25(3):472–482. https://doi.org/10.1007/s10897-015-9897-6 CrossRefPubMed

Platten U, Rantala J, Lindblom A, Brandberg Y, Lindgren G, Arver B (2012) The use of telephone in genetic counseling versus in-person counseling: a randomized study on counselees’ outcome. Fam Cancer 11(3):371–379. https://doi.org/10.1007/s10689-012-9522-x CrossRefPubMedPubMedCentral

10.

Rothwell E, Kohlmann W, Jasperson K, Gammon A, Wong B, Kinney A (2012) Patient outcomes associated with group and individual genetic counseling formats. Fam Cancer 11(1):97–106. https://doi.org/10.1007/s10689-011-9486-2 CrossRefPubMed

11.

Sie AS, Spruijt L, van Zelst-Stams WA, Mensenkamp AR, Ligtenberg MJ, Brunner HG, Prins JB, Hoogerbrugge N (2016) High satisfaction and low distress in breast cancer patients one year after BRCA-mutation testing without prior face-to-face genetic counseling. J Genet Couns 25(3):504–514. https://doi.org/10.1007/s10897-015-9899-4 CrossRefPubMed

12.

Pal T, Lee JH, Besharat A, Thompson Z, Monteiro AN, Phelan C, Lancaster JM, Metcalfe K, Sellers TA, Vadaparampil S, Narod SA (2014) Modes of delivery of genetic testing services and the uptake of cancer risk management strategies in BRCA1 and BRCA2 carriers. Clin Genet 85(1):49–53. https://doi.org/10.1111/cge.12130 CrossRef

13.

Hartmann LC, Lindor NM (2016) Risk-reducing surgery in hereditary breast and ovarian cancer. N Engl J Med 374(24):2404. https://doi.org/10.1056/NEJMc1602861 CrossRefPubMed

14.

Nilsson MP, Nilsson ED, Silfverberg B, Borg A, Loman N (2018) Written pretest information and germline BRCA1/2 pathogenic variant testing in unselected breast cancer patients: predictors of testing uptake. Genet Med. https://doi.org/10.1038/s41436-018-0021-9 CrossRefPubMed

15.

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRefPubMed

16.

Kurian AW, Sigal BM, Plevritis SK (2010) Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol 28(2):222–231. https://doi.org/10.1200/JCO.2009.22.7991 CrossRefPubMed

17.

Ayme A, Viassolo V, Rapiti E, Fioretta G, Schubert H, Bouchardy C, Chappuis PO, Benhamou S (2014) Determinants of genetic counseling uptake and its impact on breast cancer outcome: a population-based study. Breast Cancer Res Treat 144(2):379–389. https://doi.org/10.1007/s10549-014-2864-3 CrossRefPubMed

18.

Moller P, Hagen AI, Apold J, Maehle L, Clark N, Fiane B, Lovslett K, Hovig E, Vabo A (2007) Genetic epidemiology of BRCA mutations–family history detects less than 50% of the mutation carriers. Eur J Cancer (Oxford, England: 1990) 43(11):1713–1717. https://doi.org/10.1016/j.ejca.2007.04.023 CrossRef

19.

Nilsson MP, Winter C, Kristoffersson U, Rehn M, Larsson C, Saal LH, Loman N (2017) Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer. Fam Cancer 16(2):187–193. https://doi.org/10.1007/s10689-016-9953-x CrossRefPubMedPubMedCentral

20.

Wood ME, Kadlubek P, Pham TH, Wollins DS, Lu KH, Weitzel JN, Neuss MN, Hughes KS (2014) Quality of cancer family history and referral for genetic counseling and testing among oncology practices: a pilot test of quality measures as part of the American Society of Clinical Oncology Quality Oncology Practice Initiative. J Clin Oncol 32(8):824–829. https://doi.org/10.1200/jco.2013.51.4661 CrossRefPubMedPubMedCentral

Title: High patient satisfaction with a simplified BRCA1/2 testing procedure: long-term results of a prospective study
Authors: Martin P. Nilsson
Erik D. Nilsson
Åke Borg
Yvonne Brandberg
Barbro Silfverberg
Niklas Loman
Publication date: 01-01-2019
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-5000-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2019

Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score

Predictors of time to death after distant recurrence in breast cancer patients

Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?

A randomized trial of interpersonal psychotherapy, problem solving therapy, and supportive therapy for major depressive disorder in women with breast cancer

One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis

Extranodular extension in sentinel lymph node-positive breast cancer might predict further initiation of completion axillary lymph node dissection

Keynote webinar | Spotlight on antibody–drug conjugates in cancer